Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug Administration's website showed on Wednesday.

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and weight loss not meeting patients' expectations.

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.

England's National Health Services will offer Eli Lilly's weight-loss drug to nearly a quarter million people as part of a three-year plan, the country's drugs cost regulator said on Thursday. The drug,

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 medications. Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.

Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss drugs are scrambling to figure out if they’ll still have access after US regulators signaled an end to their unfettered use.

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.

A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies against skirting regulatory standards to put them on the market now that shortages are waning.

Key Takeaways Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration (FDA) said Eli Lilly's popular weight-loss drugs are no longer on its list of drugs in short supply. The FDA allows companies to produce compounded copycat drugs when the originals are hard to obtain,